GLP-1 receptor agonists are licensed in the UK for type 2 diabetes mellitus and specific weight management indications, not for cognitive impairment or dementia GLP-1 receptors are present in brain regions involved in memory and learning, prompting research into potential neuroprotective effects Ongoing clinical trials, including studies of semaglutide in Alzheimer's disease, are examining whether these medications benefit cognitive function Common adverse effects include gastrointestinal symptoms
Furthermore, VPA reduces the release of the epileptogenic -hydroxybutyric acid and attenuates the neuronal excitation induced by N -methyl-D-aspartate (NMDA)-type glutamate receptors [9]
These alterations contribute to metabolic dysregulation by modulating lipid absorption, glucose metabolism, and inflammatory signaling
Clinical Corner Benefits of using CGM with GLP-1 drugs for diabetes treatment Published: Jan
PMID: 40125190 15 In older women, a high-protein diet including animal-sourced foods did not impact serum levels and urinary excretion of trimethylamine-N-oxide
